既往EVAR后行开窗腔内动脉瘤修复的中期结局与瘤囊动态变化
该研究纳入2008至2021年荷兰两家医院因复杂腹主动脉瘤行开窗腔内动脉瘤修复(FEVAR)的196例患者,其中27%(n=53)既往接受过EVAR。既往EVAR者5年内主动脉相关干预风险更高(HR 2.6,95%CI 1.1-6.5,p=.037),1年瘤囊扩张率更高(48%,n=21/44 vs 8%,n=9/110,p<.001),但死亡率无显著差异。
要点
- 既往EVAR后FEVAR患者5年内主动脉相关干预风险高于初次FEVAR(HR 2.6,95%CI 1.1-6.5,p=.037)。
- 既往EVAR后FEVAR患者1年瘤囊扩张率48%(n=21/44),高于初次FEVAR的8%(n=9/110),p<.001;瘤囊退缩率更低。
- 两组死亡率无显著差异,但既往EVAR后FEVAR的中期生存不受影响。
核心结论
- 既往EVAR后FEVAR患者较初次FEVAR患者瘤囊扩张率高且需更多二次干预,但未影响中期生存。
- 未来研究需评估既往EVAR后FEVAR是否为有效干预,以及驱动成功FEVAR后瘤囊生长的潜在过程。
研究设计与样本
- 荷兰两家医院2008至2021年因复杂腹主动脉瘤行FEVAR的患者,分为初次FEVAR组和既往EVAR后FEVAR组,共196例,其中27%(n=53)有既往EVAR史。
- 分析采用Kaplan-Meier法、多变量Cox回归分析、卡方检验和线性混合效应模型。
主要发现
- 既往EVAR后FEVAR患者年龄显著高于初次FEVAR组(78±6.7岁 vs 73±5.9岁,p<.001)。
- 两组死亡率无显著差异。
- 既往EVAR后FEVAR患者5年内主动脉相关干预风险更高(HR 2.6;95%CI 1.1-6.5,p=.037)。
- 在154例有影像学资料的患者中,既往EVAR后FEVAR患者1年瘤囊扩张率48%(n=21/44),初次FEVAR组8%(n=9/110),p<.001;瘤囊退缩率更低。
- 随时间瘤囊动态变化结果相似:既往EVAR后FEVAR组瘤囊增长,初次FEVAR组瘤囊缩小(p<.001)。
关键数值与推荐
- 既往EVAR后FEVAR组5年内主动脉相关干预风险HR 2.6(95%CI 1.1-6.5,p=.037)。
- 1年瘤囊扩张率:既往EVAR后FEVAR组48%(n=21/44) vs 初次FEVAR组8%(n=9/110),p<.001。
- 随时间瘤囊动态变化组间比较p<.001。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 未来研究需评估既往EVAR后FEVAR是否为有效干预,以及驱动成功FEVAR后瘤囊生长的潜在过程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fenestrated endovascular aneurysm repair (FEVAR) is a feasible option for aortic repair after endovascular aneurysm repair (EVAR), due to improved peri-operative outcomes compared with open conversion. However, little is known regarding the durability of FEVAR as a treatment for failed EVAR. Since aneurysm sac evolution is an important marker for success after aneurysm repair, the aim of the study was to examine midterm outcomes and aneurysm sac dynamics of FEVAR after prior EVAR. METHODS: Patients undergoing FEVAR for complex abdominal aortic aneurysms from 2008 to 2021 at two hospitals in The Netherlands were included. Patients were categorised into primary FEVAR and FEVAR after EVAR. Outcomes included five year mortality rate, one year aneurysm sac dynamics (regression, stable, expansion), sac dynamics over time, and five year aortic related procedures. Analyses were done using Kaplan-Meier methods, multivariable Cox regression analysis, chi square tests, and linear mixed effect models. RESULTS: One hundred and ninety-six patients with FEVAR were identified, of whom 27% (n = 53) had had a prior EVAR. Patients with prior EVAR were significantly older (78 ± 6.7 years vs. 73 ± 5.9 years, p < .001). There were no significant differences in mortality rate. FEVAR after EVAR was associated with a higher risk of aortic related procedures within five years (hazard ratio [HR] 2.6; 95% confidence interval [CI] 1.1 - 6.5, p = .037). Sac dynamics were assessed in 154 patients with available imaging. Patients with a prior EVAR showed lower rates of sac regression and higher rates of sac expansion at one year compared with primary FEVAR (sac expansion 48%, n = 21/44, vs. 8%, n = 9/110, p < .001). Sac dynamics over time showed similar results, sac growth for FEVAR after EVAR, and sac shrinkage for primary FEVAR (p < .001). CONCLUSION: There were high rates of sac expansion and a need for more secondary procedures in FEVAR after EVAR than primary FEVAR patients, although this did not affect midterm survival. Future studies will have to assess whether FEVAR after EVAR is a valid intervention, and the underlying process that drives aneurysm sac growth following successful FEVAR after EVAR.
引用
- Sulzer TAL, de Bruin JL, Rastogi V, et al. Midterm Outcomes and Aneurysm Sac Dynamics Following Fenestrated Endovascular Aneurysm Repair after Previous Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2024. PMID: 38301871. doi:10.1016/j.ejvs.2024.01.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。